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Andrade Pereira, Rayana de Castro da Paz and Regiane Tigulini de 
Souza Jordão insightful discussions on the best way to present the 
data of this manuscript. 
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Are antigenic tests useful for detecting SARS-CoV-2 
infections in patients accessing to emergency 
departments? Results from a North-West Italy hospital 
Dear Editor, 
In the article “Clinical application of a rapid antigen test for 
the detection of SARS-CoV-2 infection in symptomatic and asymp- 
tomatic patients evaluated in the emergency department: A pre- 
liminary report.”, 1 Turcato et al. presented a study on the use of 
rapid antigenic tests (Ag-RDTs) instead of the usual real time re- 
verse transcription polymerase chain reaction (RT-PCR) assay to de- 
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Fig. 1. Positive and negative predictive value estimates in relation to prevalence, using the sensitivity and specificity of the test found in our population (sensitivity = 0.800; 
specificity = 0.939). 
tect the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- 
CoV-2) in the context of Emergency Departments (ED). They ob- 
served a general good sensitivity and specificity, lower in the sub- 
group of asymptomatic patients. Their conclusion is in favour of 
the use of Ag-RDTs in EDs as an additional tool to address the chal- 
lenge of containing the SARS-CoV-2 pandemic. 
We agree with the authors that the development of reliable but 
cheaper and faster point-of-care diagnostic tests was expected to 
be useful either for population-screening or as first aid tests in the 
emergency room. 2 , 3 Data on the sensitivity and specificity of cur- 
rently available Ag-RDTs derive from studies that vary in design, 
setting, population and type of specimen, thus strongly limiting 
the comparability and ability to make general inferences. Sensitiv- 
ity appears to be highly variable, ranging from 29 to 94% compared 
to the RT-PCR test, but specificity is consistently high ( > 97%). 4–7 
Ag-RDTs were found to perform better in patients with high viral 
loads (Ct values ≤25 or > 106 genomic virus copies/mL) 5 , 7 , 8 which 
usually happens in the pre-symptomatic (0.5–3 days before symp- 
tom onset) and early symptomatic phases of the illness (within 
the first week from symptom onset) but limited data are available 
about other possible individual modifiers of the accuracy of the as- 
say. A recent Cochrane review highlighted that patients’ character- 
istics were not available or poorly detailed in many studies, with 
only three out of 22 studies coming from an ED setting. 8 
Between October 26th and November 10th 2020, 455 patients 
accessed the ED of San Luigi Gonzaga University Hospital in Or- 
bassano (Turin, Italy) and 324 underwent both RT-PCR and Ag-RDT 
testing. This period corresponds to the first two weeks of the sec- 
ond pandemic wave, with a weekly incidence of SARS-CoV-2 in- 
fection in the Region of about 500 confirmed cases/100,000 inhab- 
itants. Data were obtained as part of an observational study de- 
scribed elsewhere 9 and a detailed presentation of methods is avail- 
able in supplementary material. 
The prevalence of SARS-CoV-2 infection in this cohort was 65% 
measured using RT-PCR as a gold standard. Supplementary Table 1 
reports test results: 275 (84%) patients showed concordant results 
(168 positive and 107 negative), while 49 (15%) showed discordant 
results (42 patients had a positive RT-PCR and a negative Ag-RDT 
and 7 vice versa). Cohen’s Kappa Statistics ( k = 0.68 – 95% CI 0.61–
0.77) highlighted substantial agreement. Specificity and sensitivity 
of Ag-RDT were 0.939 (95% CI: 0.895–0.983) and 0.800 (95% CI: 
0.746–0.854), respectively, taking RT-PCR as the reference. Over- 
all, the Ag-RDT positive predictive value was 0.960 (95% CI 0.931–
0.989), and the negative predictive value was 0.718 (95% CI: 0.646–
0.790). The variation of positive and negative predictive values due 
to difference in prevalence can be observed in Supplementary Ta- 
ble 2 and Fig. 1 . Positive predictive value could vary from 0.12, 
when the prevalence of the disease is 0.01, to 0.77 when the preva- 
lence is 0.20. The negative predictive value could vary from about 
1, considering a low prevalence (0.01) to 0.95, considering a higher 
prevalence (0.20). 
No difference in patients’ characteristics between true posi- 
tive and false negative tests was observed (Supplementary Ta- 
ble 3). On the contrary, false negative patients were significantly 
younger and they were tested significantly later after symptoms 
onset compared with true negative patients ( Table 1 ). Moreover, 
fever (64.3% vs 19.6%, p < 0.0 0 01) and cough (42.9% vs 15.0%, 
p = 0.0 0 03) were significantly more frequent in false than true neg- 
atives, while chronic obstructive pulmonary disease was more fre- 
quent in true than false negatives, with a borderline significance 
(16.5% vs 4.8%, p = 0.06). Few true negative patients had bilateral 
pneumonia ( n = 10, 9.4%), that was highly present in false nega- 
tive patients ( n = 25, 61.0%, p -value for difference < 0.0 0 01) and 
multivariable analysis confirm these results, suggesting that wrong 
group allocation for negative patients occurred more frequently in 
patients with fever, cough, and pneumonia, while it was less likely 
in patients with COPD. 
The infection prevalence and the clinical context where the test 
is used affect the effectiveness of the test itself 10 : the ideal test 
in a crowded ED context should help in identifying asymptomatic 
patients arriving to the ED for reasons other than COVID-19, who 
are concurrently found COVID-19 positive. 
Our results suggest that a negative Ag-RDT test should not ex- 
clude COVID-19 in patients that clinically have symptoms that are 
strongly suggestive of COVID-19. Ag-RDTs alone had a low negative 
predictive value (we cannot trust a negative result of the test), thus 
they need to be evaluated in association with clinical judgement. A 
high level of suspicion should be maintained in patients with fever, 
cough or pneumonia notwithstanding a negative Ag-RDT. Since the 
predictive value is strictly related to the prevalence of disease, and 
then to the pre-test odds, Ag-RDTs are not really useful in settings 
where the prevalence of disease is high or in patients with high 
pre-test odds. On the contrary, in periods with low prevalence of 
the disease or in patients with a low pre-test odds (asymptomatic) 
or with symptoms probably related to a known COPD, Ag-RDTs can 
be used alone and we can trust a negative result. 
In conclusion, our results confirm the limits of antigenic tests as 
first line screening tests in settings with high prevalence of disease 
Letters to the Editor / Journal of Infection 83 (2021) 237–279 259 
Table 1 
Ag-RDT negative patients: comparison of patients’ characteristics between true negative and false negative patients. Wilcoxon sum rank test (quantitative variables) and 
chi-square or Fisher’s exact test (qualitative variables) are used and multivariable logistic model (including significant variables) to evaluate the association between being a 
false negative and patients’ characteristics. 
True negative ( n = 107) Mean 
(SD), medianor Frequency (%) 
False negative ( n = 42) Mean 
(SD), medianor Frequency (%) 
P -values OR(95% CI) 
Age, years 68.4 (18.6), med: 74.4 63.1 (16.3), med: 64.4 0.03 For 1 year increase 
1.00 (0.96 – 1.03) 
Days from symptoms onset 3.9 (6.7), med: 2 6.3 (4.7), med: 6 0.0 0 03 For 1 day increase 
1.06 (0.97 – 1.16) 
NEWS at arrival 2.1 (3.0), med: 1 2.4 (2.5), med: 2 0.14 
Symptoms 
Fever 21 (19.6%) 27 (64.3%) < 0.0 0 01 4.31 (1.30 – 14.28) 
Cough 16 (15.0%) 18 (42.9%) 0.0 0 03 5.72 (1.63 – 20.07) 
Dyspnoea 33 (30.8%) 16 (38.1%) 0.40 
Respiratory failure 16 (15.1%) 8 (19.1%) 0.56 
Gastrointestinal symptoms 29 (27.1%) 7 (16.7%) 0.18 
Anosmia 0 (0.0%) 2 (4.8%) 0.07 ∗
Ageusia 6 (5.6%) 3 (7.1%) 0.72 
Asthenia 15 (14.0%) 11 (26.2%) 0.08 
Comorbidities 
Obesity 5 (6.2%) 1 (2.8%) 0.66 ∗
Hypertension 43 (41.7%) 13 (31.0%) 0.22 
Diabetes 17 (16.5%) 5 (11.9%) 0.48 
Heart disease 26 (25.2%) 7 (16.7%) 0.26 
COPD 17 (16.5%) 2 (4.8%) 0.06 ∗ 0.12 (0.01 – 1.29) 
Cancer 18 (17.5%) 4 (9.5%) 0.31 ∗
immunosuppression 8 (7.8%) 1 (2.4%) 0.45 ∗
neurological disease 14 (13.7%) 4 (9.5%) 0.59 ∗
Pneumonia 
No 87 (82.1%) 12 (29.3%) < 0.0 0 01 Reference 
Monolateral 9 (8.5%) 4 (9.8%) 4.12 (0.59 – 28.60) 
Bilateral 10 (9.4%) 25 (61.0%) 14.89(4.14 – 53.52) 
∗ Fisher’s exact test. 
or in patients with high pre-test odds, where a negative test is not 
informative (i.e. in ED in a pandemic period). This suggests that in 
these situations the antigenic test should be integrated in a clinical 
algorithm. 
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Clinical efficacy of nitric oxide nasal spray (NONS) for the 
treatment of mild COVID-19 infection 
Dear Editor, 
Summary 
Baek et al. 1 investigated the duration of COVID-19 virus shed- 
ding in infected patients and demonstrated that even in patients 
demonstrating prolonged viral clearance, the virus was no longer 
viable after 15 days post onset of symptoms. Our study aimed to 
measure whether nitric oxide nasal spray (NONS) could accelerate 
the reduction in SARS-CoV-2 RNA load versus control with a saline 
spray. Our study recruited 80 participants who were divided into a 
NONS treatment or a placebo arm to test the efficacy of NONS as 
a treatment for mild COVID-19 infection. 
Introduction 
The coronavirus (COVID-19) pandemic has had a profound im- 
pact on the world, resulting in a worldwide death toll of over 2.6 
million and global cases in excess of 119 million as at March 2021. 2 
These figures demonstrate the necessity of rapidly developing new 
and effective ways in which to control and treat the virus in sup- 
port of the emergency use of already-available COVID-19 vaccines. 3 
There are currently no evidence-based treatments for mild 
COVID-19 infection. This double-blind phase IIb clinical trial used a 
placebo control to evaluate the efficacy of nitric oxide in the treat- 
ment of mild, symptomatic COVID-19 infection in the form of a 
self-administered nasal spray. Nitric oxide (NO) is a free radical gas 
molecule involved in innate immunity, as well as wound healing, 
vasodilation, neurotransmission, and angiogenesis. 4 Although pro- 
duced physiologically, NO has been shown to exhibit a number of 
antimicrobial actions at therapeutic dosage regimens both in vitro 
and in vivo . 5–7 
Materials and methods 
This trial was carried out at Ashford and St. Peter’s Hospi- 
tals NHS Foundation Trust (ASPHFT). 80 adults (18–70 years) who 
were isolated with mild COVID-19 infection confirmed by labora- 
tory SARS-CoV-2 RT-PCR nasal and throat swab within the 48 h of 
randomisation were eligible for recruitment. Participants were ran- 
domised 1:1 to receive NONS ( n = 40) placebo ( n = 40). The nasal 
sprays were self-administered 5–6 times daily (two sprays per nos- 
tril/dose, 120–140 µL of solution/spray) for 9 days. 
Treatment with NONS or placebo commenced on day 1. Par- 
ticipants took self-sampled nasal and throat swabs on days 1 (at 
baseline, before initiating treatments), 2, 4, and 6 in the mornings, 
prior to treatment. Quantitative RT-PCR was carried out at Berk- 
shire Surrey Pathology Services Virology laboratory to determine 
SARS-CoV-2 RNA levels. SARS-CoV-2 sequencing for variants was 
performed at Public Health England Colindale. Daily self-reporting 
questionnaires on symptoms, compliance, and treatment tolerance 
were completed by patients and follow-up continues for a total of 
18 days. 
Results 
Patients in both trial groups started on NONS or placebo at 
least 4 days after the onset of symptoms and were well bal- 
anced in terms of risk factors ( Table 1 ). 34 (85%) of the NONS 
group and the placebo group were determined to be lineage B.1.1.7 
(VOC202012/01) and the remainder were not determined to be a 
variant of concern. There were no serious adverse events in pa- 
tients within either trial group. NONS versus placebo started on 
at least day 4 of symptom onset was independently associated 
with an accelerated decrease in log(10) SARS-CoV-2 RNA concen- 
tration of −1.21 (95% CI, −2.07 to −0.35; P = 0.01) and −1.21 (95% 
CI, −2.19 to −0.24; P = 0.02) on days 2 and 4 respectively ( Fig. 1 ). 
Mean SARS-CoV-2 RNA concentration was lower on NONS by a fac- 
tor of 16.2 at days 2 and 4. A rapid reduction (95%) in the SARS- 
CoV-2 viral load was observed within 24 hours, with a 99% reduc- 
tion observed within 72 hours with NONS treatments. 
The mean SARS-CoV-2 RNA concentration at day 6 was lowered 
to −3.32 on NONS, with a treatment difference of −0.98 (95% CI, 
−2.04 to 0.08; P = 0.069). The mean treatment difference using an 
area under curve estimate from baseline through day 6 was −5.22 
with a 95% CI, −9.14 to −1.31; P = 0.001), where the mean change 
was −10.17 for the NONS group and −4.95 for the placebo group. 
40 subjects (15 NONS and 25 placebo subjects) completed and 
returned the trial assessment questionnaire. A total of 46.7% (7 
of 15) of NONS respondents reported feeling better versus 8% (2 
of 25) of placebo respondents on treatment. NONS subjects typi- 
cally reported being better by day 2-4 on treatment, whereas the 
placebo subjects typically did not report feeling better until after 
day 5. 
Fig. 1. Mean Log(10) SARS-CoV-2 RNA at days 1 to 6 
Shown is the difference in the change from baseline in SARS-CoV-2 RNA between 
the active (NONS) group and the placebo (saline) group from day 1 to day 6. The I 
bars represent standard error. 
